Literature DB >> 7350045

Bile acid-induced inhibition of the lymphoproliferative response to phytohemagglutinin and pokeweed mitogen: an in vitro study.

L Gianni, F Di Padova, M Zuin, M Podda.   

Abstract

The effects of free and conjugated bile acids on the lymphoproliferative response to phytohemagglutinin (PHA) or pokeweed mitogen (PWM) have been investigated in vitro. Significant inhibition of lymphocyte transformation was observed with 250 mumol/liter of either chenodeoxycholic (CDCA) or cholic acid (CA); the former caused more pronounced inhibition at higher concentrations. This was true whichever mitogen was present. Conjugated bile acids caused lesser degrees of inhibition than the respective free bile acids and the glycoconjugates were more inhibitory than the respective tauroconjugates of the same bile acid. At concentrations of free bile acids which completely suppressed lymphocyte transformation, no cytotoxic effects or impairment of cell viability were detected. Since the concentrations that inhibited the lymphoproliferative response were markedly lower than those reported to induce cell membrane damage, the activity observed can be attributed to a metabolic effect within the cell. Inhibition by bile acids of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase activity, resulting in a reduction of the endogenous cholesterol synthesis required for cell growth and proliferation, might account for our observations. Our results contribute to understanding the nature of the serum-dependent inhibition of lymphocyte transformation reported to exist in cholestatic liver disease.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7350045

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  13 in total

1.  Delayed homograft rejection following common bile duct ligation: in vivo evidence that obstructive jaundice is immunosuppressive.

Authors:  R M Keane; P B Collins; A H Johnson; D Bouchier Hayes
Journal:  Ir J Med Sci       Date:  1986-05       Impact factor: 1.568

2.  Suppression of immunoglobulin production of rat lymphocytes by bile acids.

Authors:  K Yamada; B O Lim; M Sugano
Journal:  In Vitro Cell Dev Biol Anim       Date:  1993-11       Impact factor: 2.416

3.  Hazards of biliary tract surgery.

Authors:  P Hayes; W S Hislop; P E Ross; R C Potts
Journal:  Br Med J (Clin Res Ed)       Date:  1981-09-12

4.  Hazards of biliary tract surgery.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1981-06-27

5.  Does preoperative percutaneous biliary drainage reduce operative risk or increase hospital cost?

Authors:  H A Pitt; A S Gomes; J F Lois; L L Mann; L S Deutsch; W P Longmire
Journal:  Ann Surg       Date:  1985-05       Impact factor: 12.969

6.  Influence of diabetes on mortality and morbidity following operations for obstructive jaundice.

Authors:  M R Keighley; G Razay; M G Fitzgerald
Journal:  Ann R Coll Surg Engl       Date:  1984-01       Impact factor: 1.891

7.  Effects of bile acids and lectins on immunoglobulin production in rat mesenteric lymph node lymphocytes.

Authors:  B O Lim; K Yamada; M Sugano
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-06       Impact factor: 2.416

8.  Intracellular accumulation of unconjugated bilirubin inhibits phytohemagglutin-induced proliferation and interleukin-2 production of human lymphocytes.

Authors:  Y Haga; M A Tempero; D Kay; R K Zetterman
Journal:  Dig Dis Sci       Date:  1996-07       Impact factor: 3.199

9.  Ursodeoxycholic acid corrects defective natural killer activity by inhibiting prostaglandin E2 production in primary biliary cirrhosis.

Authors:  Y Nishigaki; H Ohnishi; H Moriwaki; Y Muto
Journal:  Dig Dis Sci       Date:  1996-07       Impact factor: 3.199

10.  Changes in extrathymic T cells in the liver and intestinal intraepithelium in mice with obstructive jaundice.

Authors:  Kimihiko Ueno; Tetsuo Ajiki; Hisami Watanabe; Toru Abo; Yoshifumi Takeyama; Hirohiko Onoyama; Yoshikazu Kuroda
Journal:  World J Surg       Date:  2004-02-17       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.